04/15/2026 | Press release | Distributed by Public on 04/15/2026 07:26
| |
Minh Van Ngo
Andrew M. Wark Cravath, Swaine & Moore LLP Two Manhattan West 375 Ninth Avenue New York, NY 10001 (212) 474-1000 |
| |
Scott A. Abramowitz
Craig E. Marcus Ropes & Gray LLP 1211 Sixth Avenue New York, NY 10036 (212) 596 9000 |
| |
Stephen Leitzell
Michael Darby Dechert LLP Cira Centre 2929 Arch Street, Philadelphia, PA 19104 (215) 994-4000 |
| |
Allison R. Schneirov
Christopher M. Barlow Skadden, Arps, Slate, Meagher & Flom LLP One Manhattan West New York, NY 10001 (212) 735-3000 |
|
|
a. |
☒ |
The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities Exchange Act of 1934. |
|
b. |
☐ |
The filing of a registration statement under the Securities Act of 1933. |
|
c. |
☐ |
A tender offer. |
|
d. |
☐ |
None of the above. |
|
Exhibit No.
|
| |
Description
|
|
| (a)(2)(i) | | | | |
| (a)(2)(ii)* | | | Form of Proxy Card. | |
| (a)(2)(iii) | | | | |
| (a)(2)(iv) | | | | |
| (a)(5)(i) | | | | |
| (c)(i) | | | | |
| (c)(ii) | | |
Discussion materials prepared by Wells Fargo Securities, LLC and JPMorgan Securities LLC, dated March 1, 2026, for the Buyer Consortium.
|
|
| (c)(iii) | | |
Discussion materials prepared by Wells Fargo Securities, LLC and JPMorgan Securities LLC, dated November 2025, for the Buyer Consortium.
|
|
| (c)(iv) | | |
Discussion materials prepared by Goldman Sachs & Co. LLC, dated December 23, 2025, for the Special Committee of the Board of Directors of Select Medical Holdings Corporation.
|
|
| (c)(v) | | |
Discussion materials prepared by Goldman Sachs & Co. LLC, dated January 12, 2026, for the Special Committee of the Board of Directors of Select Medical Holdings Corporation.
|
|
| (c)(vi) | | |
Discussion materials prepared by Goldman Sachs & Co. LLC, dated January 29, 2026, for the Special Committee of the Board of Directors of Select Medical Holdings Corporation.
|
|
| (c)(vii) | | |
Discussion materials prepared by Goldman Sachs & Co. LLC, dated February 6, 2026, for the Special Committee of the Board of Directors of Select Medical Holdings Corporation.
|
|
| (c)(viii) | | |
Discussion materials prepared by Goldman Sachs & Co. LLC, dated February 8, 2026, for the Special Committee of the Board of Directors of Select Medical Holdings Corporation.
|
|
| (c)(ix) | | |
Discussion materials prepared by Goldman Sachs & Co. LLC, dated February 10, 2026, for the Special Committee of the Board of Directors of Select Medical Holdings Corporation.
|
|
| (c)(x) | | |
Discussion materials prepared by Goldman Sachs & Co. LLC, dated February 23, 2026, for the Special Committee of the Board of Directors of Select Medical Holdings Corporation.
|
|
| (c)(xi) | | |
Discussion materials prepared by Goldman Sachs & Co. LLC, dated February 25, 2026, for the Special Committee of the Board of Directors of Select Medical Holdings Corporation.
|
|
| (c)(xii) | | |
Discussion materials prepared by Goldman Sachs & Co. LLC, dated February 28, 2026, for the Special Committee of the Board of Directors of Select Medical Holdings Corporation.
|
|
| (c)(xiii) | | |
Discussion materials prepared by Goldman Sachs & Co. LLC, dated March 2, 2026, for the Special Committee of the Board of Directors of Select Medical Holdings Corporation.
|
|
| (c)(xiv) | | |
Discussion materials prepared by Goldman Sachs & Co. LLC, dated March 11, 2026, for the Special Committee of the Board of Directors of Select Medical Holdings Corporation.
|
|
| (d)(i) | | | |
|
Exhibit No.
|
| |
Description
|
|
| (d)(ii) | | | | |
| (d)(iii) | | | | |
| (d)(iv) | | | | |
| (d)(v) | | | | |
| (d)(vi) | | | | |
| (d)(vii) | | | | |
| (d)(viii) | | | | |
| (d)(ix) | | | | |
| (d)(x) | | |
Equity Commitment Letter, dated March 2, 2026, by and between WCAS XIV, L.P. and Stallion Intermediate Corporation.
|
|
| (d)(xi) | | |
Limited Guaranty, dated March 2, 2026, by and between WCAS XIV, L.P. and Stallion Intermediate Corporation.
|
|
| (d)(xii) | | |
Amended and Restated Debt Commitment Letter, dated March 14, 2026, by and among JPMorgan Chase Bank, N.A., Wells Fargo Bank, National Association, Wells Fargo Securities, LLC, Bank of America, N.A., BofA Securities, Inc., Deutsche Bank AG New York Branch, Deutsche Bank Securities Inc., Truist Bank, Truist Securities, Inc., Royal Bank of Canada, The Bank of Nova Scotia, Mizuho Bank, Ltd., Capital One, National Association, PNC Bank, National Association, PNC Capital Markets LLC, Fifth Third Bank, National Association and Stallion Intermediate Corporation.
|
|
| (f) | | | Section 262 of the DGCL. | |
| (g) | | | Not Applicable. | |
| 107 | | | Filing Fee Table. | |